Tissue Regenix Group's (Tissue Regenix Group PLC (AIM:TRX, OTC:TSSNF)) Danny Lee and David Cocke join Katie to talk about its first half of 2022 performance, which was strong in spite of the Covid hangover on elective surgery.
Group revenues for the period are expected to be approximately US$11.8mln, a 25% increase from the prior year.
BioRinse maintained its momentum and the commercial reorganisation of the dCELL segment began to show benefits as it too returned to growth.